Participant Flow Module
The Participant Flow Module provides information about the flow of participants through each stage of the clinical trial. This includes pre-assignment details, recruitment information, and the types of units analyzed, helping researchers understand how participants move through the study.
Participant Flow Module path is as follows:
Study -> Results Section -> Participant Flow Module
Participant Flow Module
Ignite Creation Date:
2025-12-24 @ 6:31 PM
Ignite Modification Date:
2025-12-25 @ 4:01 PM
NCT ID:
NCT05141357
Pre Assignment Details:
Subjects had to satisfy screening criteria prior to treatment with HBI-8000 + Pembrolizumab. The screening period could be up to 28 days and was comprised of assessing medical history, concomitant therapies, clinical laboratory testing, and other clinical assessments to document the subject met all inclusion criteria and none of the exclusion criteria.
Recruitment Details:
This was a multicenter (9 sites in the US: hospital, regional medical, and research centers), open label, Phase 2 study of HBI 8000 in combination with an approved dose of pembrolizumab as a first line checkpoint inhibitor therapy for advanced or metastatic non-small cell lung cancer (NSCLC). Recruitment was from 15Feb 2022 to 01Sep2022. In December 2022, enrollment was suspended.
Study:
NCT05141357
Study Brief:
Results Section:
NCT05141357